FDA: Benicar's benefits outweigh risks in hypertension patients
Last June, the FDA investigated the blood pressure drug olmesartan (Benicar, Daiichi Sankyo) after two clinical trials showed that the drug increased the rate of death from a cardiovascular cause in patients with type 2 diabetes. Last week, the agency ruled that the drug's benefits outweigh its potential risks, but only in high blood pressure patients. (Source: Cardiovascular Business News)div id=medwormpbiMedWorm Message:/i/b Please support the a href=http://www.doctorsinchains.org/ target=_blankDoctors In Chains/a campaign for the a href=http://www.doctorsinchains.org/medics/a tortured and sentenced for up to 15 years in a href=http://www.doctorsinchains.org/Bahrain/a. a href=https://twitter.com/#!/search/%23FreeDoctors#FreeDoctors/a/p/div
BENICAR(R) And BENICAR HCT(R) Effectively Reduces Blood Pressure In Elderly Patients
Daiichi Sankyo, Inc. announced today that new data presented at the American Society of Hypertension, Inc. (ASH) Annual Scientific Meeting and Exposition (ASH 2009) in San Francisco from the BeniSILVER study found that BENICAR(R) and BENICAR HCT(R) provided a mean reduction in 24-hour ambulatory systolic blood pressure (SBP) of 25. (Source: Health News from Medical News Today)
